- Home
- Publications
- Publication Search
- Publication Details
Title
Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis
Authors
Keywords
-
Journal
CIRCULATION RESEARCH
Volume 128, Issue 10, Pages 1554-1575
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2021-05-14
DOI
10.1161/circresaha.121.318187
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy
- (2020) Dhruv S. Kazi et al. CIRCULATION
- Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study
- (2020) Suzanne Lentzsch et al. JOURNAL OF CLINICAL ONCOLOGY
- Tafamidis—A Pricey Therapy for a Not-So-Rare Condition
- (2020) Jerry H. Gurwitz et al. JAMA Cardiology
- Ixazomib-dexamethasone (Ixa-Dex) vs physician’s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.
- (2020) Efstathios Kastritis et al. JOURNAL OF CLINICAL ONCOLOGY
- United network for organ sharing outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis
- (2020) Jan M. Griffin et al. CLINICAL TRANSPLANTATION
- Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation
- (2020) Christopher D. Barrett et al. JACC-Heart Failure
- Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma
- (2020) Luke T. Nelson et al. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
- Comparing Outcomes for Infiltrative and Restrictive Cardiomyopathies under the New Heart Transplant Allocation System
- (2020) Jan M. Griffin et al. CLINICAL TRANSPLANTATION
- Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data
- (2020) Nicholas J. Viney et al. ESC Heart Failure
- Clinical Experience Using Doxycycline and Ursodeoxycholic Acid for the Treatment of Transthyretin Cardiac Amyloidosis
- (2019) Erin Karlstedt et al. JOURNAL OF CARDIAC FAILURE
- The proteostasis network and its decline in ageing
- (2019) Mark S. Hipp et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy
- (2019) Daniel P. Judge et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A pair of peptides inhibits seeding of the hormone transporter transthyretin into amyloid fibrils
- (2019) Lorena Saelices et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Mechanism Of Action Of The Anti-CD38 Monoclonal Antibody Isatuximab In Multiple Myelmoa
- (2019) Laura Moreno et al. CLINICAL CANCER RESEARCH
- The pathology and changing epidemiology of Dialysis-related cardiac Beta-2 microglobulin amyloidosis
- (2019) Allison D. Morris et al. CARDIOVASCULAR PATHOLOGY
- Stabilization of amyloidogenic immunoglobulin light chains by small molecules
- (2019) Gareth J. Morgan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase 1 study of ALN-TTRsc02, a subcutaneously administered investigational RNAi therapeutic for the treatment of transthyretin-mediated amyloidosis
- (2019) David Adams et al. REVUE NEUROLOGIQUE
- Mechanistic Insights into the Early Events in the Aggregation of Immunoglobulin Light Chains
- (2019) Pinaki Misra et al. BIOCHEMISTRY
- Transthyretin Amyloid Cardiomyopathy
- (2019) Frederick L. Ruberg et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy
- (2019) Richa Manwani et al. BRITISH JOURNAL OF HAEMATOLOGY
- Rationale and Design of a Phase 3 Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
- (2019) Rodney H Falk et al. BLOOD
- Preclinical Development of an Anti-CD38 Antibody-Drug Conjugate for Treatment of Hematological Malignancies
- (2019) Lingna Li et al. BLOOD
- A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib
- (2019) Richa Manwani et al. BLOOD
- Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
- (2019) Silpa Narayanan et al. DRUG RESISTANCE UPDATES
- Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis
- (2019) Graham Lohrmann et al. JOURNAL OF CARDIAC FAILURE
- RNA-Targeted Therapeutics
- (2018) Stanley T. Crooke et al. Cell Metabolism
- Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era
- (2018) Arnt V. Kristen et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
- (2018) David Adams et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
- (2018) Merrill D. Benson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition
- (2018) Lorena Saelices et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing
- (2018) Jonathan D. Finn et al. Cell Reports
- Immunoglobulin Light Chain Amyloidosis: 2018 Update on Diagnosis, Prognosis, and Treatment
- (2018) Morie A. Gertz AMERICAN JOURNAL OF HEMATOLOGY
- Glucocorticoids in multiple myeloma: past, present, and future
- (2018) Nicholas Burwick et al. ANNALS OF HEMATOLOGY
- Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment Resistant Immunoglobulin Light Chain Amyloidosis with Multiple Myeloma
- (2018) Shumaila Muhammad Iqbal et al. Clinical Lymphoma Myeloma & Leukemia
- Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis
- (2018) Mark Miller et al. JOURNAL OF MEDICINAL CHEMISTRY
- Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio
- (2018) Eli Muchtar et al. LEUKEMIA
- Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
- (2018) Mathew S. Maurer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Venetoclax for the treatment of multiple myeloma
- (2018) Iuliana Vaxman et al. Expert Review of Hematology
- Cellular uptake and trafficking of antisense oligonucleotides
- (2017) Stanley T Crooke et al. NATURE BIOTECHNOLOGY
- Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells
- (2017) Esther Imperlini et al. Scientific Reports
- Structure of Monomeric Transthyretin Carrying the Clinically Important T119M Mutation
- (2016) Jin Hae Kim et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Effect of melphalan 140 mg/m2vs 200 mg/m2on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience
- (2016) Lakshmikanth Katragadda et al. CLINICAL TRANSPLANTATION
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
- (2016) Niels W. C. J. van de Donk et al. IMMUNOLOGICAL REVIEWS
- First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction
- (2016) Morie A. Gertz et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis
- (2016) H Landau et al. LEUKEMIA
- The activities of amyloids from a structural perspective
- (2016) Roland Riek et al. NATURE
- Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity
- (2016) Ricardo Sant'Anna et al. Nature Communications
- Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage
- (2015) Pallavi Manral et al. BIOSCIENCE REPORTS
- A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis
- (2015) G. Palladini et al. BLOOD
- Correlation of histomorphological pattern of cardiac amyloid deposition with amyloid type: a histological and proteomic analysis of 108 cases
- (2015) Brandon T Larsen et al. HISTOPATHOLOGY
- Uncovering the Mechanism of Aggregation of Human Transthyretin
- (2015) Lorena Saelices et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens
- (2015) Tilmann Bochtler et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component
- (2015) Duncan B. Richards et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
- (2015) Henk M. Lokhorst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study
- (2015) Ole B Suhr et al. Orphanet Journal of Rare Diseases
- On the lag phase in amyloid fibril formation
- (2015) Paolo Arosio et al. PHYSICAL CHEMISTRY CHEMICAL PHYSICS
- Left Ventricular Structure and Function in Transthyretin-Related Versus Light-Chain Cardiac Amyloidosis
- (2014) Candida Cristina Quarta et al. CIRCULATION
- Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients
- (2014) G Palladini et al. LEUKEMIA
- Age-Related Oxidative Modifications of Transthyretin Modulate Its Amyloidogenicity
- (2013) Lei Zhao et al. BIOCHEMISTRY
- Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
- (2013) Shauna M. Collins et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach
- (2013) G. Palladini et al. HAEMATOLOGICA
- The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
- (2013) C Touzeau et al. LEUKEMIA
- AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin
- (2013) S. C. Penchala et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Amyloidosis in autoinflammatory syndromes
- (2012) Laura Obici et al. AUTOIMMUNITY REVIEWS
- A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis
- (2012) E. Kastritis et al. BLOOD
- Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis
- (2012) A. Dispenzieri et al. BLOOD
- Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial
- (2012) S. K. Kumar et al. BLOOD
- The Amyloid State of Proteins in Human Diseases
- (2012) David Eisenberg et al. CELL
- New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
- (2012) Giovanni Palladini et al. JOURNAL OF CLINICAL ONCOLOGY
- Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
- (2012) Shaji Kumar et al. JOURNAL OF CLINICAL ONCOLOGY
- Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial
- (2012) T. Coelho et al. NEUROLOGY
- The repertoire of light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44
- (2011) V. Perfetti et al. BLOOD
- Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
- (2011) B. C. Potts et al. CURRENT CANCER DRUG TARGETS
- Radioimmunodetection of amyloid deposits in patients with AL amyloidosis
- (2010) J. S. Wall et al. BLOOD
- Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study
- (2010) P. Moreau et al. BLOOD
- Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement
- (2010) S. Dietrich et al. BLOOD
- Pressure-Volume Relationships in Patients With Transthyretin (ATTR) Cardiac Amyloidosis Secondary to V122I Mutations and Wild-Type Transthyretin
- (2010) Taslima Bhuiyan et al. Circulation-Heart Failure
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Antibodies to human serum amyloid P component eliminate visceral amyloid deposits
- (2010) Karl Bodin et al. NATURE
- Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38 MAPK pathway
- (2010) J. Shi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Transthyretin: the servant of many masters
- (2009) Joel N. Buxbaum et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Matrix Metalloproteinases and Their Tissue Inhibitors in Cardiac Amyloidosis
- (2008) Andreia Biolo et al. Circulation-Heart Failure
- Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis
- (2008) E Ihse et al. JOURNAL OF PATHOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now